Christopher C Nessel
Overview
Explore the profile of Christopher C Nessel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
5300
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Barnett A, Cyr D, Goodman S, Levitan B, Yuan Z, Hankey G, et al.
Int J Cardiol
. 2018 Mar;
257:78-83.
PMID: 29506743
Aims: The aim of this study was to determine the net clinical benefit (NCB) of rivaroxaban compared with warfarin in patients with atrial fibrillation. Methods: This was a retrospective analysis...
12.
Kochar A, Hellkamp A, Lokhnygina Y, Jones W, Becker R, Berkowitz S, et al.
Clin Cardiol
. 2018 Feb;
41(1):39-45.
PMID: 29389037
Background: Atrial fibrillation (AF) increases risk of stroke 5-fold. Carotid artery disease (CD) also augments the risk of stroke, yet there are limited data about the interplay of these 2...
13.
Chen S, Hellkamp A, Becker R, Berkowitz S, Breithardt G, Fox K, et al.
Am J Cardiol
. 2017 Sep;
120(10):1837-1840.
PMID: 28886856
The safety of intravenous thrombolysis in patients taking rivaroxaban has not been well established. We retrospectively analyzed the outcomes of all patients who received thrombolytic therapy in the Rivaroxaban Once...
14.
Washam J, Hellkamp A, Lokhnygina Y, Piccini J, Berkowitz S, Nessel C, et al.
Am J Cardiol
. 2017 Jun;
120(4):588-594.
PMID: 28645473
Non-dihydropyridine calcium channel blockers (non-DHP CCBs) possess combined P-glycoprotein and moderate CYP3A4 inhibition, which may lead to increased exposure of medications that are substrates for these metabolic pathways, such as...
15.
Leef G, Hellkamp A, Patel M, Becker R, Berkowitz S, Breithardt G, et al.
J Am Heart Assoc
. 2017 Jun;
6(6).
PMID: 28615214
Background: Although implantation of cardiac implantable electronic devices (CIEDs) in patients receiving warfarin is well studied, limited data are available on the use of oral factor Xa inhibitors in this...
16.
Balla S, Cyr D, Lokhnygina Y, Becker R, Berkowitz S, Breithardt G, et al.
Am J Cardiol
. 2017 May;
119(12):1989-1996.
PMID: 28477860
We investigated stroke outcomes in normal weight (body mass index [BMI] 18.50 to 24.99 kg/m), overweight (BMI 25.00 to 29.99 kg/m), and obese (BMI ≥30 kg/m) patients with atrial fibrillation...
17.
Sun Y, Hu D, Stevens S, Lokhnygina Y, Becker R, Berkowitz S, et al.
Thromb Res
. 2017 Apr;
156:184-190.
PMID: 28433206
Background: The ROCKET AF study evaluated once-daily rivaroxaban versus dose-adjusted warfarin for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF). In this analysis, we compared...
18.
Lindner S, Fordyce C, Hellkamp A, Lokhnygina Y, Piccini J, Breithardt G, et al.
Circulation
. 2017 Mar;
135(10):1001-1003.
PMID: 28264892
No abstract available.
19.
Shah R, Hellkamp A, Lokhnygina Y, Becker R, Berkowitz S, Breithardt G, et al.
Am Heart J
. 2016 Sep;
179:77-86.
PMID: 27595682
Background: We aimed to investigate the relationship between aspirin use and clinical outcomes in patients enrolled in Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism...
20.
Sherwood M, Cyr D, Jones W, Becker R, Berkowitz S, Washam J, et al.
JACC Cardiovasc Interv
. 2016 Aug;
9(16):1694-702.
PMID: 27539689
Objectives: The authors assessed the use of dual antiplatelet therapy (DAPT) and outcomes in patients undergoing percutaneous coronary intervention (PCI) during the ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor...